The MInT trial showed that 6 cycles of R-CHOP every 21 days (R-CHOP-21) are sufficient in younger DLBCL patients with favorable features and that patients with early-stage DLBCL (Ann Arbor I and II) and no tumor bulk (variably defined) had excellent outcomes without radiation therapy (RT), making R-CHOP x 6 an alternative to R-CHOP x 3 + RT (3). The gene discussed is DDIT3; the disease is neoplasm.